Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
PHASE1
The purpose of this study was to assess the safety and pharmacokinetics (PK...
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
PHASE1
Background:
The human body uses antibodies as one way to help fight infect...
Status
Completed
Location
University of Alabama HIV Clinic Clinical Research Site, AIDS Clinical Trials Group (ACTG)
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
PHASE1
Background:
Antibodies help the body fight infection. VRC01LS is an antibo...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike